Hashimoto's and Your Genome: Why Thyroid Autoimmunity Has a Genetic Blueprint

Hashimoto's thyroiditis is the most common autoimmune condition in the world, affecting an estimated 1 in 10 women and a smaller but significant proportion of men. It is characterised by immune system attack on thyroid tissue, leading to progressive thyroid dysfunction — typically hypothyroidism — with a wide spectrum of symptoms including fatigue, brain fog, weight changes, hair loss, depression, and cold intolerance.

Despite its prevalence, most people with Hashimoto's have never been told that their susceptibility has a substantial genetic component — that specific variants in immune regulation genes, selenoprotein genes, and thyroid function genes determined their likelihood of developing this condition and continue to influence how it progresses. Understanding these variants doesn't change the diagnosis, but it meaningfully changes the protocol.

HLA variants: The immune recognition foundation

The Human Leukocyte Antigen (HLA) system encodes proteins that present antigens to the immune system — effectively the mechanism by which your immune cells learn to distinguish self from non-self. HLA gene variants are the strongest genetic risk factors for virtually all autoimmune conditions, and Hashimoto's is no exception.

HLA-DR3 (DRB1*03) and HLA-DR5 (DRB1*11/12) are the most consistently associated HLA variants in Hashimoto's across multiple populations. These variants influence how effectively the immune system tolerates thyroid antigens — thyroglobulin and thyroid peroxidase (TPO). Carriers of these variants have immune systems that are more likely to mount an inappropriate response against thyroid tissue, particularly under conditions of immune activation such as infection, stress, or significant hormonal change (pregnancy, perimenopause).

HLA-DQ variants are also relevant, particularly in the context of the well-documented overlap between Hashimoto's and coeliac disease. HLA-DQ2 and HLA-DQ8, the primary coeliac risk variants, are overrepresented in Hashimoto's populations — which explains why gluten elimination produces meaningful symptom improvement in a subset of Hashimoto's patients (specifically those carrying both the HLA-DQ coeliac risk variants and the thyroid autoimmunity variants).

CTLA4: The immune checkpoint gene

CTLA4 (Cytotoxic T-Lymphocyte Antigen 4) encodes a protein that functions as a brake on T-cell activation — an immune checkpoint that prevents excessive immune responses. It is one of the most important regulatory mechanisms in autoimmune susceptibility, and CTLA4 variants are among the most replicated genetic associations in Hashimoto's research.

The rs231775 variant (A49G, Thr17Ala) reduces CTLA4 expression and function, impairing the T-cell brake mechanism. Carriers of the G allele have T-cells that are less effectively suppressed after activation — a pattern that predicts higher risk of autoimmune conditions broadly, and thyroid autoimmunity specifically. A 2003 meta-analysis in Human Molecular Genetics confirmed CTLA4 rs231775 as a significant risk factor for both Hashimoto's and Graves' disease across multiple ethnic populations.

The practical implication: CTLA4 loss-of-function variants indicate an immune system that is constitutively less regulated. This makes immune-modulating interventions — particularly those that support regulatory T-cell function — more relevant. Vitamin D at optimal rather than merely adequate levels (targeting 60-80 ng/mL rather than the conventional 30 ng/mL cutoff) directly influences regulatory T-cell differentiation. VDR (Vitamin D Receptor) variants frequently co-occur with Hashimoto's and further influence this pathway.

Selenoprotein genes: The thyroid's most critical cofactor

Selenium is the most important micronutrient for thyroid function, and its relevance in Hashimoto's is better supported by clinical trial evidence than almost any other nutritional intervention in autoimmune thyroiditis. The mechanism is direct: thyroid peroxidase (TPO), the enzyme central to thyroid hormone synthesis, is a selenium-dependent enzyme. The thyroid contains the highest concentration of selenium per gram of tissue of any organ in the body.

SELENOP (selenoprotein P) is the primary selenium transport protein in the blood and a key determinant of selenium delivery to the thyroid. The rs7579 variant in the SELENOP 3' UTR is associated with reduced selenoprotein P expression and lower selenium delivery to tissues including the thyroid. Carriers of this variant may have functionally lower thyroid selenium availability even with adequate dietary intake or standard supplementation doses.

GPX1 (Glutathione Peroxidase 1) rs1050450 affects the activity of a key selenoprotein antioxidant enzyme. The thyroid produces significant hydrogen peroxide as a byproduct of hormone synthesis — GPX1 is part of the antioxidant defence that protects thyroid tissue from this oxidative burden. Reduced GPX1 activity leaves thyroid tissue more vulnerable to oxidative damage, which amplifies autoimmune inflammation.

Clinical trial evidence supports selenium supplementation in Hashimoto's: a 2002 trial in Journal of Clinical Endocrinology & Metabolism showed that 200mcg daily of selenomethionine significantly reduced anti-TPO antibody levels over 3 months. Multiple subsequent trials have replicated this finding. However, selenium has a narrow therapeutic window — excess selenium is toxic. Dosing should be informed by baseline selenium status and, where available, selenoprotein gene variants that influence individual requirements.

PTPN22 and TPO variants

PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22) rs2476601 is another broadly relevant autoimmune risk variant — it encodes a protein involved in T-cell receptor signalling, and the risk allele reduces the threshold for T-cell activation. Like CTLA4, PTPN22 variants indicate a more reactive immune baseline. PTPN22 rs2476601 is associated with Hashimoto's, rheumatoid arthritis, type 1 diabetes, and lupus — its presence signals a general autoimmune susceptibility rather than thyroid-specific risk.

TPO (Thyroid Peroxidase) variants directly affect the enzyme that is the primary target of anti-TPO antibodies in Hashimoto's. Variants that alter TPO protein structure may influence how recognisable the enzyme is to the immune system — a structural factor in antigen presentation. This is an area of ongoing research.

Why gluten matters for some but not all

The gluten-Hashimoto's connection is real but genotype-dependent. Molecular mimicry between gliadin (a gluten protein) and thyroid antigens has been proposed as one mechanism — the immune system trained to attack gluten may cross-react with thyroid tissue. But the evidence is strongest in people who carry both HLA-DQ coeliac variants and thyroid autoimmunity variants.

For people without HLA-DQ2/DQ8 variants and without clinical or subclinical coeliac disease, strict gluten elimination may produce little benefit. For those with both the coeliac HLA variants and Hashimoto's, gluten elimination is mechanistically justified and supported by clinical observation. Your HLA genotype is the relevant factor — not generic advice.

What a DNA report changes about Hashimoto's management

Standard Hashimoto's management is: diagnose by TSH and anti-TPO antibodies, prescribe levothyroxine when TSH rises above threshold, monitor annually. This approach treats the endpoint of a process that has often been running for years and ignores the upstream mechanisms that determine how aggressively the condition progresses.

Knowing your HLA variants tells you whether gluten elimination is mechanistically justified. Knowing your CTLA4 and PTPN22 status tells you how reactive your immune baseline is and how aggressively you should prioritise immune regulation. Knowing your selenoprotein variants tells you whether standard selenium supplementation doses are likely sufficient or whether you need higher doses or a different form. Knowing your VDR variants tells you whether conventional Vitamin D targets are adequate for your receptor sensitivity.

These are not marginal refinements. They are the difference between a generic autoimmune protocol and one built around your specific immune architecture.

Want this applied to your actual variant profile?

Inflammation & Immune DNA Report · $79 →